{"disease":{"id":"relapsed-hodgkin-s-disease-adult","name":"relapsed hodgkin s disease adult"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04776265","title":"RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Grupo Argentino de Tratamiento de la Leucemia Aguda","has_results":false},{"nct_id":"NCT04464590","title":"Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT05595447","title":"Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Hospital Regional de Alta Especialidad del Bajio","has_results":false},{"nct_id":"NCT04938232","title":"Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}